Atrium Therapeutics, Inc.
RNABiotechnology
$8.26−1.67%As of Oct 29vs prior close
- Market cap
- $141.3M
- P/E (TTM)
- –
- From 52W high
- −50.06%
- EPS (LTM)
- -$5.44
- Revenue (LTM)
- $35.8M
- Net margin
- -260.00%
Nomior Score
40
Steady ProfileBottom 30% of the scored universe
Growth49
Quality41
Value42
Momentum—
Resilience44
Growth
+38.09%revenue a year over 2 fiscal years
YE23 $9.8MLTM $35.8M
Connections
Revenue to profitYE25
The net loss was 412% of revenue, wider by 181 pts on a year.
Who owns it
2funds